• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

    12/29/22 5:15:07 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email
    SC 13G/A 1 ea170991-13ga1briley_journey.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Journey Medical Corporation
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    48115J109
    (CUSIP Number)
     
    December 27, 2022
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒ Rule 13d-1(b)

     

      ☐ Rule 13d-1(c)

     

      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. 48115J109  

     

    1 Names of Reporting Persons
    B. Riley Financial, Inc.
    2 Check the appropriate box if a member of a Group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    DE

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5 Sole Voting Power
    0
    6 Shared Voting Power
    864,695
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    864,695

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    864,695
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    4.9%*
    12 Type of Reporting Person (See Instructions)
    CO

     

    * Percent of class is calculated based on 17,704,325 shares of common stock, par value $0.0001 (the “Common Stock”) of Journey Medical Corporation (the “Issuer”) outstanding as reported by the Issuer on Form 10-Q filed with the Securities & Exchange Commission (the “SEC”) on November 10, 2022.

     

    2

     

     

    CUSIP No. 48115J109  

      

    1 Names of Reporting Persons
    B. Riley Securities, Inc.
    2 Check the appropriate box if a member of a Group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    DE

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5 Sole Voting Power
    0
    6 Shared Voting Power
    864,695
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    864,695

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    864,695
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    4.9%*
    12 Type of Reporting Person (See Instructions)
    BD

     

    * Percent of class is calculated based on 17,704,325 shares of the Common Stock of the Issuer outstanding as reported by the Issuer on Form 10-Q filed with the SEC on November 10, 2022.

     

    3

     

     

    CUSIP No. 48115J109  

     

    1 Names of Reporting Persons
    Bryant R. Riley
    2 Check the appropriate box if a member of a Group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    United States of America

    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5 Sole Voting Power
    0
    6 Shared Voting Power
    864,695
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    864,695

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    864,695
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    4.9%*
    12 Type of Reporting Person (See Instructions)
    IN

     

    * Percent of class is calculated based on 17,704,325 shares of the Common Stock of the Issuer outstanding as reported by the Issuer on Form 10-Q filed with the SEC on November 10, 2022.

     

    4

     

     

    Item 1.

     

    (a) Name of Issuer: Journey Medical Corporation

     

    (b) Address of Issuer’s Principal Executive Offices: 9237 E Via de Ventura Blvd, Suite 105, Scottsdale, AZ 85258  

     

    Item 2(a). Name of Persons Filing:

     

    B. Riley Financial, Inc., a Delaware corporation (“BRF”),

    B. Riley Securities, Inc., a Delaware corporation (“BRS”), and

    Bryant R. Riley, an individual.

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The principal business address of each of BRF, BRS and Bryant R. Riley is:

    11100 Santa Monica Blvd. Suite 800

    Los Angeles, CA 90025

     

    Item 2(c). Citizenship:

     

    BRF and BRS are organized under the laws of the State of Delaware.

    Bryant R. Riley is a citizen of the United States of America.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share

     

    Item 2(e). CUSIP Number:

     

    48115J109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  

     

    Not applicable

     

      (a) ☒ Broker or dealer registered under Section 15 of the Act;
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
      (j) ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    5

     

     

    Item 4. Ownership

     

    (a) Amount Beneficially Owned:

     

    As of the date hereof, BRS directly owned 864,695 shares of common stock of the Issuer. As of the date hereof, BRF may beneficially own 864,695 shares of common stock of the Issuer, which are held directly by BRS, one of BRF’s indirect wholly owned subsidiaries.

     

    As of the date hereof, Bryant R. Riley may beneficially own 864,695 shares of common stock of the Issuer held directly by BRS in the manner specified in the paragraph above.

     

    The foregoing should not be construed as an admission by any Reporting Person as to beneficial ownership of any Common Shares owned by another Reporting Person. Each of the Reporting Persons disclaims beneficial ownership of the Common Shares that are not directly owned by such Reporting Person, except to the extent of their pecuniary interest therein.

     

    (b) Percent of Class:

     

    As of the date hereof, BRS directly owned 4.9% of the outstanding shares of common stock of the Issuer. As of the date hereof, BRF as the parent company of BRS may be deemed to have beneficially owned 4.9% of the outstanding shares of common stock of the Issuer directly owned by BRS.

     

    As of the date hereof, Bryant R. Riley may beneficially own 4.9% of the outstanding shares of common stock of the Issuer held directly by BRS in the manner specified in the paragraph above.

     

    The foregoing should not be construed as an admission by any Reporting Person as to beneficial ownership of any Common Shares owned by another Reporting Person. Each of the Reporting Persons disclaims beneficial ownership of the Common Shares that are not directly owned by such Reporting Person, except to the extent of their pecuniary interest therein.

     

    (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote: See cover page Items 5-9.

     

      (ii) Shared power to vote or to direct the vote: See cover page Items 5-9.

     

      (iii) Sole power to dispose or to direct the disposition of: See cover page Items 5-9.

     

      (iv) Shared power to dispose or to direct the disposition of: See cover page Items 5-9.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not Applicable.

     

    Item 8. Identification and classification of members of the group.

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 29, 2022

     

      B. RILEY FINANCIAL, INC.
         
      By: /s/ Bryant R. Riley
      Name:  Bryant R. Riley
      Title:  Co-Chief Executive Officer
         
      B. RILEY SECURITIES, INC.
         
      By: /s/ Andrew Moore
      Name: Andrew Moore
      Title: Chief Executive Officer
         
      BRYANT R. RILEY
         
      By: /s/ Bryant R. Riley

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     

     7

     

     

    Get the next $DERM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DERM

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    More analyst ratings

    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty rev

      5/15/25 4:05:12 PM ET
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    SEC Filings

    See more

    $DERM
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation

      SCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)

      5/15/25 4:15:24 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Journey Medical Corporation

      10-Q - Journey Medical Corp (0001867066) (Filer)

      5/15/25 6:01:35 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      5/14/25 4:05:58 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

      SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief

      5/1/24 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Journey Medical with a new price target

      Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00

      2/25/22 9:05:17 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

      SC 13G/A - Journey Medical Corp (0001867066) (Subject)

      12/29/22 5:15:07 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      8/17/22 4:01:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maraoui Claude sold $33,065 worth of shares (4,834 units at $6.84), decreasing direct ownership by 0.21% to 2,348,313 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:52 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $16,478 worth of shares (2,409 units at $6.84), decreasing direct ownership by 1% to 203,557 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:22 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Alloush Ramsey sold $19,542 worth of shares (2,857 units at $6.84), decreasing direct ownership by 0.56% to 504,817 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:31:11 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rosenwald Lindsay A Md bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 7% to 144,245 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/27/24 7:00:16 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maraoui Claude bought $34,790 worth of shares (10,000 units at $3.48), increasing direct ownership by 0.46% to 2,163,430 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:03:29 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Justin Adam bought $104,100 worth of shares (30,000 units at $3.47), increasing direct ownership by 29% to 134,717 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:02:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care